睿智医药：接受国新证券等投资者调研

Company Overview - Ruizhi Pharmaceutical (SZ 300149) announced that on November 13, 2025, it will accept investor research led by Guoxin Securities, with CFO Cha Yinqun addressing investor questions [1] - As of the report, Ruizhi Pharmaceutical has a market capitalization of 5.8 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of Ruizhi Pharmaceutical is as follows: - Pharmaceutical research and development services and production outsourcing accounted for 99.06% - Prebiotic series accounted for 0.52% - Rental income accounted for 0.35% - Other industries accounted for 0.07% [1]